Quoin Pharmaceuticals (NASDAQ: QNRX) is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of novel therapeutics for oncology and inflammatory diseases. The company’s research platform integrates precision medicine approaches with targeted small molecules and antibody therapies. Quoin’s mission is to address unmet medical needs by advancing therapies that modulate key biological pathways involved in tumor growth, immune regulation, and chronic inflammation.
The company’s pipeline comprises multiple preclinical and clinical-stage candidates. Its lead asset, QNRX-101, is being evaluated in a Phase II trial for advanced solid tumors, where it targets a novel receptor implicated in tumor proliferation. In parallel, Quoin is developing QNRX-205, an antibody-drug conjugate designed to deliver cytotoxic agents selectively to malignant cells. Preclinical studies have demonstrated favorable safety profiles and promising efficacy signals, supporting ongoing clinical investigations.
Founded in 2017 and headquartered in Boston, Massachusetts, Quoin Pharmaceuticals operates research facilities in both the United States and Europe. The company’s global footprint enables collaboration with academic institutions and contract research organizations to accelerate the translation of laboratory discoveries into clinical candidates. Quoin maintains strategic partnerships to bolster its manufacturing capabilities and to facilitate late-stage clinical trials across North America and select international markets.
Under the leadership of Chief Executive Officer Michael Nguyen, Ph.D., Quoin Pharmaceuticals has expanded its scientific advisory board to include experts in oncology, immunology, and drug development. The management team combines experience from leading pharmaceutical and biotech companies, providing expertise in regulatory affairs, clinical operations, and commercial strategy. Quoin’s governance framework emphasizes rigorous oversight and transparent communication with investors and stakeholders as it advances toward key clinical milestones.
AI Generated. May Contain Errors.
Free QNRX Stock Alerts